Resumo

ALVAREZ DELGADO, Yamilé  e  SANTANA PEREZ, Felipe. Valvular heart disease associated with use of dopaminergic agonists in patients with hyperprolactinemia. Rev Cubana Endocrinol [online]. 2009, vol.20, n.3, pp. 152-162. ISSN 1561-2953.

Cabergoline and bromocriptine are dopaminergic agonists drugs used in hyperprolactinemia treatment, as well as in patients with Parkinson's disease. Among its adverse effects considered as "very inusual" is included the ability to induce fibrotic changes in cardiac valvular tract first described in patients with Parkinson disease using doses higher than those usually used in hyperprolactinemia treatment. Some studies have mentioned the evidence on these facts and of the possible mechanisms causing the valvular affection. Until now, there are not much researches on this subject in patients with hyperprolactinemia, but most indicated that its use in this kind of patient can not to produce a clinically relevant valvular afection, fact tha may to be related to the dose used (on average 10 times lower than those used in Parkinson's disease); however, some subclinical anomalies have been detected in valvular tract. Due to this novel subject and the scarce evident of these facts in patients treated by hyperprolactinemia, we offered an review of the subject.

Palavras-chave : dopaminergic agonists; valvular heart disease; hyperprolactinemia.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )